KR100920560B1 - 당뇨병을 예방하거나 치료하기 위한 상승작용성 약제학적배합물 - Google Patents

당뇨병을 예방하거나 치료하기 위한 상승작용성 약제학적배합물 Download PDF

Info

Publication number
KR100920560B1
KR100920560B1 KR1020047000748A KR20047000748A KR100920560B1 KR 100920560 B1 KR100920560 B1 KR 100920560B1 KR 1020047000748 A KR1020047000748 A KR 1020047000748A KR 20047000748 A KR20047000748 A KR 20047000748A KR 100920560 B1 KR100920560 B1 KR 100920560B1
Authority
KR
South Korea
Prior art keywords
group
formula
pharmaceutical
pharmaceutically suitable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047000748A
Other languages
English (en)
Korean (ko)
Other versions
KR20040029371A (ko
Inventor
졸탄 스질바시
기요르기 라블록즈키
페터 리터라티나기
Original Assignee
엔-진 리서치 래버러토리스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by 엔-진 리서치 래버러토리스 인코포레이티드 filed Critical 엔-진 리서치 래버러토리스 인코포레이티드
Publication of KR20040029371A publication Critical patent/KR20040029371A/ko
Application granted granted Critical
Publication of KR100920560B1 publication Critical patent/KR100920560B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
KR1020047000748A 2001-07-17 2002-07-10 당뇨병을 예방하거나 치료하기 위한 상승작용성 약제학적배합물 Expired - Fee Related KR100920560B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HUP0102982 2001-07-17
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HUP0202204 2002-07-05
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (2)

Publication Number Publication Date
KR20040029371A KR20040029371A (ko) 2004-04-06
KR100920560B1 true KR100920560B1 (ko) 2009-10-08

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047000748A Expired - Fee Related KR100920560B1 (ko) 2001-07-17 2002-07-10 당뇨병을 예방하거나 치료하기 위한 상승작용성 약제학적배합물

Country Status (21)

Country Link
US (2) US7635674B2 (enExample)
EP (1) EP1408966B1 (enExample)
JP (1) JP4598390B2 (enExample)
KR (1) KR100920560B1 (enExample)
CN (1) CN1270713C (enExample)
AT (1) ATE386523T1 (enExample)
AU (1) AU2002354884B2 (enExample)
BR (1) BR0210744A (enExample)
CA (2) CA2682251A1 (enExample)
CY (1) CY1107939T1 (enExample)
DE (1) DE60225143T2 (enExample)
DK (1) DK1408966T3 (enExample)
ES (1) ES2300460T3 (enExample)
IL (2) IL159412A0 (enExample)
MX (1) MXPA04000324A (enExample)
NO (1) NO20040153L (enExample)
NZ (1) NZ531155A (enExample)
PL (1) PL205826B1 (enExample)
PT (1) PT1408966E (enExample)
RU (1) RU2311907C2 (enExample)
WO (1) WO2003007951A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807093A2 (en) * 2004-10-13 2007-07-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
JP5951752B2 (ja) 2011-04-13 2016-07-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｔｐ１ｂ発現のアンチセンス調節
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021242916A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328906A (en) * 1988-10-20 1994-07-12 Biorex Kutato-Fejleszto Kft 0-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328906A (en) * 1988-10-20 1994-07-12 Biorex Kutato-Fejleszto Kft 0-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same

Also Published As

Publication number Publication date
US7635674B2 (en) 2009-12-22
KR20040029371A (ko) 2004-04-06
IL159412A0 (en) 2004-06-01
CA2452558A1 (en) 2003-01-30
CA2452558C (en) 2009-12-22
PL205826B1 (pl) 2010-05-31
ATE386523T1 (de) 2008-03-15
CA2682251A1 (en) 2003-01-30
ES2300460T3 (es) 2008-06-16
PL364662A1 (en) 2004-12-13
AU2002354884A2 (en) 2003-03-03
BR0210744A (pt) 2004-07-20
NO20040153L (no) 2004-03-16
JP4598390B2 (ja) 2010-12-15
AU2002354884B2 (en) 2007-10-18
DK1408966T3 (da) 2008-06-16
DE60225143D1 (de) 2008-04-03
WO2003007951A1 (en) 2003-01-30
US8048873B2 (en) 2011-11-01
IL159412A (en) 2009-09-22
RU2004105149A (ru) 2005-04-20
RU2311907C2 (ru) 2007-12-10
PT1408966E (pt) 2008-05-02
JP2004537550A (ja) 2004-12-16
EP1408966A1 (en) 2004-04-21
CY1107939T1 (el) 2013-09-04
EP1408966B1 (en) 2008-02-20
DE60225143T2 (de) 2009-02-12
NZ531155A (en) 2005-07-29
MXPA04000324A (es) 2004-07-23
CN1531433A (zh) 2004-09-22
US20070015687A1 (en) 2007-01-18
US20100048627A1 (en) 2010-02-25
CN1270713C (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
US8048873B2 (en) Synergistic pharmaceutical combination for the prevention or treatment of diabetes
CN100348189C (zh) DPP－IV抑制剂与PPAR－α化合物的组合
KR100566701B1 (ko) 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP2004537550A5 (enExample)
EP1648453A1 (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes
HUP0400762A2 (hu) Gyógyászati készítmény a diabetesz megelőzésére vagy kezelésére
AU1591699A (en) Statin-matrix metalloproteinase inhibitor combinations
JP4588448B2 (ja) ＰＰＡＲγアゴニストによる治療に伴う体重増加を治療するためのＰＰＡＲαアゴニストの使用
KR20070104913A (ko) 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
CN1840195A (zh) 一种用于预防或治疗糖尿病的协同药物组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20121224

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20131219

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20150116

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150930

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150930